Sage Therapeutics (SAGE) News Today $6.94 -0.14 (-1.98%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Scotiabank Remains a Buy on SAGE Therapeutics (SAGE)January 21 at 3:44 PM | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)January 21 at 3:44 PM | markets.businessinsider.comSage Therapeutics Receives Acquisition Proposal from BiogenCAMBRIDGE, Mass., January 10, 2025 — Sage Therapeutics, Inc. (NASDAQ: SAGE) recently disclosed that it has received an unsolicited and non-binding acquisition proposition from Biogen Inc. TheJanuary 20 at 2:06 AM | americanbankingnews.comSage sues Biogen in wake of $469M buyout offer: reportJanuary 17, 2025 | msn.comSage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in DecemberSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 4,830,000 shares, a drop of 24.6% from the December 15th total of 6,410,000 shares. Currently, 9.0% of the shares of the company are short sold. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 4.7 days.January 15, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from AnalystsJanuary 15, 2025 | americanbankingnews.comSage takeout bid implies zero enterprise value, says MizuhoJanuary 14, 2025 | markets.businessinsider.comSage Therapeutics takeover bid undervalues Zurzuvae, says TruistJanuary 14, 2025 | markets.businessinsider.comBiogen proposes acquisition of partner Sage TherapeuticsJanuary 14, 2025 | msn.comBiogen Wants to Buy Its Partner Sage for Almost No PremiumJanuary 13, 2025 | msn.comSage Therapeutics shares surge on unsolicited takeover bid from BiogenJanuary 13, 2025 | proactiveinvestors.comSage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover BidJanuary 13, 2025 | investopedia.comSage Therapeutics Stock Rockets 35% Higher After Takeover Bid From BiogenJanuary 13, 2025 | barrons.comSage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2025 | businesswire.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Hold" from BrokeragesSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned an average rating of "Hold" from the twenty research firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and twoJanuary 12, 2025 | marketbeat.comSage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from BiogenJanuary 10, 2025 | businesswire.comSage Therapeutics (NASDAQ:SAGE) Shares Cross Below 200-Day Moving Average - Here's WhySage Therapeutics (NASDAQ:SAGE) Share Price Passes Below 200 Day Moving Average - What's Next?January 10, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Share Price Passes Below 200 Day Moving Average - What's Next?Sage Therapeutics (NASDAQ:SAGE) Shares Cross Below 200-Day Moving Average - What's Next?January 10, 2025 | marketbeat.comSage Therapeutics price target raised to $5 from $4 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comDenali Therapeutics Maintains Strong Buy Rating Amid Setbacks, Fueled by Promising BBB PlatformJanuary 7, 2025 | markets.businessinsider.comSage Therapeutics price target lowered to $9 from $26 at Piper SandlerJanuary 3, 2025 | markets.businessinsider.comNeumora Therapeutics: Untapped Potential Amidst Ongoing Trials and Anticipated Positive DevelopmentsJanuary 2, 2025 | markets.businessinsider.comSage Therapeutics (NASDAQ:SAGE) Price Target Lowered to $9.00 at Piper SandlerPiper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday.January 2, 2025 | marketbeat.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmJanuary 1, 2025 | markets.businessinsider.comMost important biotech stories of 2024: IPOs, M&A deals and more layoffsDecember 31, 2024 | bizjournals.comState Street Corp Raises Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)State Street Corp grew its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 18.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,926,239 shares of the bioDecember 24, 2024 | marketbeat.comViridian Therapeutics: Promising THRIVE-2 Study Results Position Veligrotug as a Market Leader in Thyroid Eye Disease TreatmentDecember 17, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $6 from $10 at StifelDecember 17, 2024 | finance.yahoo.comStifel Nicolaus Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $6.00Stifel Nicolaus decreased their target price on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research note on Monday.December 16, 2024 | marketbeat.comMizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)December 12, 2024 | markets.businessinsider.comFmr LLC Sells 552,248 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Fmr LLC lowered its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 9.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 5,271,108 shares of the biopharmaceutical company's stock after selling 552,248 shares during the period.December 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $9.10 Million Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Jacobs Levy Equity Management Inc. decreased its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 11.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,260,017 shares of the bDecember 6, 2024 | marketbeat.comRTW Investments LP Boosts Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)RTW Investments LP increased its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 2.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,591,700 shares of the biopharDecember 5, 2024 | marketbeat.comSage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | businesswire.comMajor Depressive Disorder Market to Register Immense Growth by 2034 Owing to a Robust Pipeline | DelveInsightNovember 26, 2024 | finance.yahoo.comQ1 EPS Estimate for Sage Therapeutics Increased by AnalystSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued on Wednesday, November 20th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical comNovember 25, 2024 | marketbeat.comSage Therapeutics price target lowered to $4 from $7 at BofANovember 23, 2024 | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of "Hold" from AnalystsSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seventeen have issued a hoNovember 23, 2024 | marketbeat.comSage raised to sector perform by RBC in wake of drug failureNovember 22, 2024 | msn.comSage ends dalzanemdor development following Phase II trial failureNovember 22, 2024 | msn.comSAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber ChallengesNovember 22, 2024 | markets.businessinsider.comSage Therapeutics price target lowered to $9 from $10 at TD CowenNovember 22, 2024 | markets.businessinsider.comSage Therapeutics (NASDAQ:SAGE) Upgraded to "Sector Perform" at Royal Bank of CanadaRoyal Bank of Canada raised shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 target price on the stock in a report on Thursday.November 21, 2024 | marketbeat.comSage slips as Huntington’s Disease therapy fails in mid-stage trialNovember 20, 2024 | seekingalpha.comSAGE Therapeutics: Hold Rating Amid Strategic Shift Following Dalzanemdor DiscontinuationNovember 20, 2024 | markets.businessinsider.comSAGE Therapeutics: Hold Rating Amid Dalzanemdor’s Phase 2 Failure and Valuation AdjustmentsNovember 20, 2024 | markets.businessinsider.comSage Therapeutics to end development of key therapy after a third trial failureNovember 20, 2024 | msn.comSage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a report on Wednesday.November 20, 2024 | marketbeat.comSage Therapeutics scraps development of rare disease drug after it fails mid-stage studyNovember 20, 2024 | reuters.comCNS Drug Development: Same As It Ever WasNovember 19, 2024 | seekingalpha.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.410.63▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼69▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Today Wave Life Sciences News Today Apogee Therapeutics News Today Indivior News Today Galapagos News Today Structure Therapeutics News Today Arcutis Biotherapeutics News Today Evotec News Today Immunocore News Today Dyne Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free sage Stock Alerts